Research programme: cardiovascular disorder therapeutics - Ascelegen Therapeutics

Drug Profile

Research programme: cardiovascular disorder therapeutics - Ascelegen Therapeutics

Alternative Names: GDF11-related therapies - Ascelegen Therapeutics; Growth differentiation factor 11-related therapies - Ascelegen Therapeutics; Growth factor-related therapies - Ascelegen Therapeutics

Latest Information Update: 07 Jul 2014

Price : $50

At a glance

  • Originator Ascelegen Therapeutics
  • Class
  • Mechanism of Action Growth differentiation factor 11 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cardiovascular disorders

Most Recent Events

  • 19 Jun 2014 Early research in Cardiovascular disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top